According to results from a phase 2 study, sosimerasib demonstrated promise among patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer According to results from a phase 2 study, sosimerasib demonstrated promising efficacy and safety among patients...

Panelists discuss how KRAS G12C inhibitors are moving into frontline combination therapy with immunotherapy, highlighting KRYSTAL-7 data showing impressive efficacy in PD-L1–high patients (~28 months progression-free survival) but more modest results in PD-L1–low patients, with ongoing studies exploring optimal combination...

Open AccessSystematic Review KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis by Filip MarkovićFilip Marković SciProfiles Scilit Preprints.org Google Scholar 1,†, Jelena Milin-LazovićJelena Milin-Lazović SciProfiles Scilit Preprints.org Google Scholar...

Panelists discuss how critical broad-panel next-generation sequencing is for all patients with non–small cell lung cancer to enable biomarker-guided treatment, with focus on KRAS G12C mutations found in 12% to 14% of patients and consideration of PD-L1 expression levels and...

Panelists discuss how 2 FDA-approved KRAS G12C inhibitors (adagrasib and sotorasib) perform in second-line therapy after immunotherapy and chemotherapy, with both showing improved progression-free survival versus docetaxel despite modest gains, leading to their adoption as standard of care due to...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies The combination of adagrasib (Krazati) and pembrolizumab (Keytruda) demonstrated encouraging efficacy in patients with previously untreated, advanced KRAS G12C-mutated non–small cell lung cancer...

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC The combination of adagrasib (Krazati) and pembrolizumab (Keytruda) demonstrated encouraging efficacy in patients with previously untreated, advanced KRAS G12C-mutated non–small cell lung cancer (NSCLC), according to results from the...